Literature DB >> 18040796

Enhanced immune sensitivity to stress following chronic morphine exposure.

Kimberly A Ballard1, Trisha C Pellegrino, Norma C Alonzo, Alexandria L Nugent, Barbara M Bayer.   

Abstract

Chronic administration of escalating doses ofmorphine leads to neuroadaptive changes precipitating development of tolerance to many of the acute effects of morphine, such as analgesia, activation of the hypothalamic-pituitary-adrenal (HPA) axis and suppression of immune cell activities. Interestingly, morphine tolerance has also been shown to be accompanied by heightened immunosuppressive effects of restraint stress using a rodent model. These observations have led to the hypothesis that the altered neuronal state accompanying opioid tolerance may contribute to this enhanced immune sensitivity to stress. To further test this hypothesis using different stressors, Sprague-Dawley rats were treated chronically with morphine for at least 8 days and then challenged with either psychological (water stress) or systemic stressors [morphine withdrawal, lipopolysaccharide (10 mug/kg i.p. challenge)]. It was found that, independent of the type of stress employed, morphine-tolerant animals displayed significantly lower mitogen-stimulated blood lymphocyte responses when compared to the responses of similarly treated saline controls. To determine whether direct activation of central stress pathways may also lead to enhanced immune sensitivity, morphine-tolerant animals were centrally injected with IL-1beta (1 ng/mul i.c.v.), a cytokine that activates the HPA axis by central mechanisms. Similar to the other types of stress, this direct central challenge was also found to be more immunosuppressive in morphine-tolerant animals compared to controls. Collectively, these studies demonstrate that morphine-tolerant animals have an enhanced susceptibility to the debilitating effects of a variety of stressors on immune cell function, an effect that is likely due to the neuroadaptive changes that develop during chronic morphine exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18040796     DOI: 10.1007/s11481-005-9008-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   7.285


  78 in total

1.  Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine.

Authors:  Albert H Avila; Norma C Alonzo; Barbara M Bayer
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

2.  Withdrawal from morphine in mice suppresses splenic macrophage function, cytokine production, and costimulatory molecules.

Authors:  Rahil T Rahim; Joseph J Meissler; Lily Zhang; Martin W Adler; Thomas J Rogers; Toby K Eisenstein
Journal:  J Neuroimmunol       Date:  2003-11       Impact factor: 3.478

3.  Tolerance development to morphine-induced alterations of immune status.

Authors:  J P West; D T Lysle; L A Dykstra
Journal:  Drug Alcohol Depend       Date:  1997-07-04       Impact factor: 4.492

4.  The effects of morphine, nicotine and epibatidine on lymphocyte activity and hypothalamic-pituitary-adrenal axis responses.

Authors:  R D Mellon; B M Bayer
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

5.  Potential role of the autonomic nervous system in the immunosuppressive effects of acute morphine administration.

Authors:  L R Flores; K L Dretchen; B M Bayer
Journal:  Eur J Pharmacol       Date:  1996-12-30       Impact factor: 4.432

6.  Immunomodulatory effects of morphine withdrawal in the rat are time dependent and reversible by clonidine.

Authors:  J P West; L A Dykstra; D T Lysle
Journal:  Psychopharmacology (Berl)       Date:  1999-10       Impact factor: 4.530

7.  Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat.

Authors:  N Quan; E L Stern; M B Whiteside; M Herkenham
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

8.  Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control the pituitary-adrenocortical axis in rats.

Authors:  Maria Luisa Laorden; Maria Teresa Castells; Maria Victoria Milanés
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

9.  Drug addiction: functional neurotoxicity of the brain reward systems.

Authors:  F Weiss; G F Koob
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

10.  Brain corticotropin-releasing factor immunoreactivity and receptors in five inbred rat strains: relationship to forced swimming behaviour.

Authors:  A Lahmame; D E Grigoriadis; E B De Souza; A Armario
Journal:  Brain Res       Date:  1997-03-07       Impact factor: 3.252

View more
  4 in total

Review 1.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

2.  Attenuation of morphine analgesic tolerance by rosuvastatin in naïve and morphine tolerance rats.

Authors:  Yongle Li; Yinyin Shu; Qing Ji; Jian Liu; Xiaoyun He; Weiyan Li
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 3.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

4.  Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site.

Authors:  Josephine L Martin; Lisa Koodie; Anitha G Krishnan; Richard Charboneau; Roderick A Barke; Sabita Roy
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.